

## ASTRO School of Radiation Oncology—Online Courses

### Red Journal CME

#### Biosketch Information

**Anthony V. D'Amico, M.D., Ph.D.**

Professor of Radiation Oncology  
Harvard Medical School  
Boston, MA

#### **Educational Preparation:**

**Institution:** Massachusetts Institute of Technology, Cambridge, MA

**Degree(s) Earned:** 1983 - B.S., Physics, B.S., Nuclear Engineering

1984 - M.S., Nuclear Engineering

1986 - Ph.D., Radiation Physics

**Institution:** University of Pennsylvania School of Medicine, Philadelphia, PA

**Degree(s) Earned:** 1990 - M.D., Medicine

#### **Select Papers:**

- **D'Amico AV**, Whittington R, Malkowicz SB, Schnall M, Tomaszewski JE, Schultz D, and Wein A. A multivariate analysis of clinical and pathological factors which predict for Prostate-Specific antigen failure after radical prostatectomy for prostate cancer. *J. Urol.* 154:131-138,1995.
- **D'Amico AV** and Coleman CN. The Role Of Interstitial Radiotherapy In The Management Of Clinically Organ Confined Prostate Cancer: The Jury Is Still Out. *J Clinical Oncology.* 14:304-315,1996.
- **D'Amico AV**, Whittington R, Tomaszewski JE, Malkowicz SB, Schultz D, Schnall M, and Wein A. A critical appraisal of the role of endorectal coil magnetic resonance imaging in the prediction of pathologic stage and postoperative prostate specific antigen failure in patients with clinically organ confined prostate cancer. *Journal of Clinical Oncology* 14:1770-1777,1996.
- **D'Amico AV**, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, and Wein A. PSA Failure Despite Pathologic Organ Confined Disease: The Basis for and Adjuvant Therapy Trial. *Journal of Clinical Oncology* 15:1465-1469,1997.
- **D'Amico AV**, Whittington R, Kaplan I, Beard C, Schultz D, Malkowicz SB, Wein A, Tomaszewski JE, and Coleman CN. Calculated Prostate Cancer Volume: The Optimal Predictor of 3 year bNED after Surgery or Radiation Therapy in Patients with a Pre-Treatment PSA 4-20 ng/ml. *Cancer* 82:334-341,1998.
- **D'Amico AV**, Schnall M, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, and Wein A. Endorectal Coil Magnetic Resonance Imaging Identifies Locally Advanced Prostate Cancer In Select Patients With Clinically Localized Disease. *Urology* 51:449-454,1998.

- **D'Amico AV**, Desjardin A, Chen M, Schultz D, Tomaszewski JE, Malkowicz SB, Wein A, Renshaw A, Loughlin K, and Richie JP. Assessment Of Outcome Prediction Models For Localized Prostate Cancer In Patients Managed With Radical Prostatectomy Or External Beam Radiation Therapy. *Cancer*. 82:1887-96,1998.
- **D'Amico AV**, Whittington R, Broderick GA, Malkowicz SB, Schultz D, Tomaszewski JE, Kaplan I, Beard C and Wein A. Biochemical Outcome after Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy For Clinically Localized Prostate Cancer. *J Am Med Assoc* 280:969-974,1998.
- **D'Amico AV**, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Renshaw A, Loughlin KR, Richie JP, and Wein A. A calculated prostate cancer volume > 4.0 cm<sup>3</sup> Identifies Patients with Localized Prostate Cancer who have a poor prognosis Following Radical Prostatectomy or External Beam radiation Therapy. *J Clin Oncol* 16:3094-3100,1998.
- **D'Amico AV**, Cormack R, Tempany CM, Kumar S, Toupless G, Kooy HM, and Coleman CN Real time Magnetic resonance image guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys* 42:507-516,1998.
- **D'Amico AV**, Whittington R, Malkowicz SB, Fondurulia J, Chen M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, and Coleman CN A Pre-Treatment Nomogram for Prostate Specific Antigen Recurrence Following Radical Prostatectomy or External Beam Radiation Therapy for Clinically Localized Prostate Cancer. *J Clin Oncol* 17:168-172,1999.
- **D'Amico AV**, Renshaw AA, Arsenault L, Schultz D, Richie JP. Clinical Predictors Of Upgrading To Gleason Grade 4 Or 5 Disease At Radical Prostatectomy: Potential Implications On Patient Selection For Radiation And Androgen Suppression Therapy. *Int J Radiat Oncol Biol Phys* 45:841-846, 1999.
- **D'Amico AV**, Renshaw AA, Schultz D, Rocha S, Richie JP. The Impact of The Biopsy Gleason Score On PSA Outcome For Prostate Cancer Patients With PSA  $\leq$  10 ng/ml And T1c, 2a: Implications On Patient Selection For Prostate Only Therapy. *Int J Radiat Oncol Biol Phys* 45:847-851, 1999.
- **D'Amico, A.V.**, Whittington, R., Malkowicz, S.B., Schultz, D., Fondurulia, J. Chen, M., Tomaszewski, J.E., Renshaw, A.A., C. Wein, Richie, J.P. The Clinical Utility Of The Percent Of Positive Prostate Biopsies In Defining Biochemical Outcome Following Radical Prostatectomy For Patients With Clinically Localized Prostate Cancer. *J Clin Oncol* 2000;18:1164-1172.
- **D'Amico, A.V.**, Whittington, R., Malkowicz, S.B., Wu, Y.H., Chen M. H., Art, M., Tomaszewski, J.E., Wein, A. The Combination Of The Preoperative PSA Level, Biopsy Gleason Score, Percent Positive Biopsies And MRI T-Stage To Predict Early PSA Failure In Men With Clinically Localized Prostate Cancer. *Urology* 55:572-576, 2000.
- **D'Amico AV**, Whittington, R., Malkowicz, SB, Schultz, D., Tomaszewski JE, Wein A.: Prostate Specific Antigen Outcome Based on the Extent of Extracapsular Extension and Margin Status in Patients with Seminal Vesicle Negative Prostate Carcinoma of Gleason Score  $\leq$  7. *Cancer* 88: 2110-2115; 2000.

- **D'Amico, A.V.**, Whittington, R., Malkowicz, S.B., Wu, Y.H., Chen M. H., Hurwitz, M., Kantoff, P., Tomaszewski, J.E., Renshaw, A.A., Wein, A., Richie, J.P. Utilizing Predictions Of Early Prostate-Specific Antigen Failure To Optimize Patient Selection For Adjuvant Therapy Trials. *J Clin Oncol.* 18:3240-3246, 2000.
- **D'Amico AV**, Whittington R, Malkowicz SB, Schnall M, Schultz D, Cote K, Tomaszewski JE, Wein A. Endorectal Magnetic Resonance Imaging As A Predictor Of Biochemical Outcome Following Radical Prostatectomy For Men With Clinically Localized Prostate Cancer. *J Urol* 164: 759-763, 2000.
- **D'Amico AV**, Weinstein M, Li X, Richie JP, Fujimoto J. Optical Coherence Tomography as a Method For Identifying Benign And Malignant Microscopic Structures In The Prostate Gland. *Urology* 55: 783-787, 2000.
- **D'Amico AV**, Schultz D, Schneider L, Hurwitz M, Kantoff PW, Richie JP. Comparing Prostate Specific Antigen Outcomes After Different Types Of Radiotherapy Management Of Clinically Localized Prostate Cancer Highlights The Importance Of Controlling For Established Prognostic Factors. *J Urol* 163: 1797-1801, 2000.
- **D'Amico AV**, Cormack R, Kumar S, Tempany CM. Real-Time Magnetic Resonance Imaging-Guided Brachytherapy in the Treatment of Selected Patients with Clinically Localized Prostate Cancer. *Journal of Endourology* 14: 367-370, 2000.
- **D'Amico AV**, Tempany CM, Cormack R, Hata N, Jinzaki M, Tuncali K, Weinstein M, Richie JP. Transperineal Magnetic Resonance Image Guided Prostate Biopsy. *J Urol* 164: 385-387; 2000
- **D'Amico AV**, Schultz, D, Loffredo, M, Dugal, R, Hurwitz, M, Kaplan, I, Beard, CJ, Renshaw, AA, Kantoff, PW. Biochemical Outcome Following External Beam Radiation Therapy With Or Without Androgen Suppression Therapy For Men With Clinically Localized Prostate Cancer. *JAMA* 284: 1280-1283, 2000.
- Hata N, Jinzaki M, Kacher D, Cormack R, Gering D, Silverman SG, **D'Amico AV**, Kikinis R, Jolesz FA, Tempany CM. MR imaging-guided prostate biopsy with surgical navigation software: device validation and feasibility. *Radiology* 220;263-268, 2001.
- **D'Amico AV**, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer. *Prostate Cancer and Prostatic Diseases.* 3:259-264, 2000.
- Cormack RA, **D'Amico AV**, Hata N, Silverman S, Weinstein M, Tempany CM. Feasibility of transperineal prostate biopsy under interventional MR guidance. *Urology* 56:663-664, 2000.
- **D'Amico AV**, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Perineural Invasion As A Predictor Of Biochemical Outcome Following Radical Prostatectomy For Select Men With Clinically Localized Prostate Cancer, *J Urol* 165:126-130, 2000.
- Thomas MD, Cormack R, Tempany CM, Kumar S, Manola J, Schneider L, Hurwitz MD, **D'Amico AV**. Identifying the predictors of acute urinary retention

- following magnetic-resonance image guided prostate brachytherapy. *Int J Radiat Oncol Biol Phys* 47: 905-908, 2000.
- **D'Amico AV**, Cormack R, Kumar S, Tempany CM. Real-Time Magnetic Resonance Imaging-Guided Brachytherapy in the Treatment of Selected Patients with Clinically Localized Prostate Cancer. *J Endourology* 14:367-370, 2000.
  - Kooy HM, Cormack RA, Mathiowitz G, Tempany CM, **D'Amico AV**. A Software System for Interventional Magnetic Resonance Image Guided Prostate Brachytherapy. *Int J Comp Aided Surgery*, 5:401-413, 2000.
  - Cormack RA, Tempany CM, **D'Amico AV**. Optimizing target coverage by dosimetric feedback during prostate brachytherapy. *Int J Radiat Oncol Biol Phys* 48:1245-1249, 2000.
  - **D'Amico AV**, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Clinical Utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate cancer. *Mol Urol* 4:171-176, 2000.
  - Lee AK, Schultz D, Renshaw AA, Richie JP, **D'Amico AV**. Optimizing patient selection for prostate monotherapy. *Int J Radiat Oncol Biol Phys*. 49:673-677, 2001.
  - Cheung R, Altschuler MD, **D'Amico AV**, Malkowicz SB, Wein AJ, Whittington R. ROC Optimization May Improve Risk Stratification of Prostate Cancer Patients. *Urology* 57:286-290, 2001.
  - **D'Amico AV**, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA. The Clinical Utility of the Percent Of Positive Prostate Biopsies in Predicting Biochemical Outcome Following External Beam Radiation Therapy for Patients With Clinically Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys* 49:679-684, 2001.
  - **D'Amico AV**, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D, Rhude M, Rocha S, Wein A, Richie JP. Predicting Prostate Specific Antigen Outcome Preoperatively in the PSA Era. *J Urol* 166:2185-2188, 2001.
  - **D'Amico AV**, Whittington R, Malkowicz SB, Renshaw A, Tomaszewski JE, Bentley C, Schultz D, Rocha S, Wein A, Richie JP. Estimating the Impact on Prostate Cancer Mortality of Incorporating Prostate-Specific Antigen Testing into Screening. *Urology* 58:406-410, 2001.
  - **D'Amico AV**, Manola J, Loffredo M, Lopes L, Nissen K, Gordon I, Tempany CM, Cormack RA. A practical method to achieve prostate gland immobilization and target verification for daily treatment. *Int J Radiat Oncol Biol Phys* 51:1431-1436, 2001.
  - Cheung R, Altschuler MD, **D'Amico AV**, Malkowicz SB, Wein AJ, Whittington R. Using the receiver operating characteristic curve to select pretreatment and path predictors for early and late postprostatectomy PSA failure. *Urology* 58:400-405, 2001.
  - **D'Amico AV**. Radiation and Hormonal Therapy for locally advanced and clinically localized prostate cancer. *Urology* 58:78-82, 2001.

- Hsiung P, Ko TH, Li XD, Fujimoto JG, Weinstein M, **D'Amico AV**, Richie JP. Intraoperative Imaging using Optical Coherence Tomography. *Optics Letters* 2002.
- Bharatha A, Hirose M, Hata N, Warfield SK, Ferrant M, Zou KH, Suarez-Santana E, Ruiz-Alzola J, **D'Amico AV**, Cormack RA, Kikinis R, Jolesz FA, Tempany CM. Evaluation of three-dimensional finite element-based deformable registration of pre- and intraoperative prostate imaging. *Med Phys* 28:2551-2561, 2001.
- **D'Amico AV**, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen M, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Biochemical Outcome Following Radical Prostatectomy Or External Beam Radiation Therapy For Clinically Localized Prostate Cancer In The PSA Era, *Cancer* 95:281-286; 2002.
- **D'Amico AV**, Keshaviah A, Manola J, Cote K, Loffredo M, Iskrzytzky O, Renshaw AA. The Clinical Utility Of The Percent Of Positive Prostate Biopsies In Predicting Prostate Cancer Specific And Overall Survival Following Radiation Therapy For Patients With Localized Prostate Cancer, *Int J Radiat Oncol Biol Phys* 2002;53:581-587.
- **D'Amico AV**, Chen M, Malkowicz SB, Whittington R, Renshaw AA, Tomaszewski JE, Samofalov Y, Wein A, Richie JP. Lower Prostate Specific Antigen Outcome than Expected following Radical Prostatectomy for Patients with High Grade Prostate Cancer and a PSA Level of 4 ng/ml or less. *J Urol* 167:2025-2031, 2002.
- **D'Amico AV**, Saegaert T, Chen M, Renshaw AA, George D, Oh W, Kantoff P. Initial Decline in Hemoglobin during Neoadjuvant Hormonal Therapy Predicts for Early PSA Failure Following Radiation and Hormonal Therapy for Patients with Intermediate and High-Risk Prostate Cancer. *Cancer* 95:275-280; 2002.
- Cross C, Schultz D, Malkowicz SB, Huang WC, Whittington R, Tomaszewski JE, Renshaw AA, Wein A, Richie JP, **D'Amico AV**. The Impact of Race on Prostate Specific Antigen Outcome Following Radical Prostatectomy for Clinically Localized Adenocarcinoma of the Prostate. *J Clin Oncol*, 2002;20:2863-2868.
- Lieberfarb M, Schultz D, Whittington R, Malkowicz SB, Tomaszewski JE, Weinstein M, Wein A, Richie JP, **D'Amico AV**. Using PSA, Biopsy Gleason Score, Clinical Stage and the Percentage of Positive Biopsies to Identify Optimal Candidates for Prostate Only Radiation Therapy. *Int J Radiat Oncol Biol Phys* 2002;53:898-903.
- Linson P, Lee A, Doytchinova, Chen MH, Weinstein MH, Richie JP, **D'Amico AV**. Percentage of core lengths involved with prostate cancer: Does it add to the percentage of positive prostate biopsies in predicting postoperative prostate – specific antigen outcome for men with intermediate-risk prostate cancer? *Urology* 2002;59:704-708.
- Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, **D'Amico AV**, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. *Cancer Cell* 2002;1:203-209.

- Hurwitz MD, Schneider L, Manola J, Beard CJ, Kaplan ID, **D'Amico AV**. Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis. *Int J Radiat Oncol Biol Phys* 2002;53:1106-1110.
- Hirose M, Bharatha A, Hata N, Zou KH, Warfield SK, Cormack RA, **D'Amico AV**, Kikinis R, Jolesz FA, Tempany CM. Quantitative MR Imaging assessment of prostate gland deformation before and during MR imaging-guided brachytherapy. *Acad Radiol* 9:906-912; 2002.
- Carroll PR, Kantoff PW, Balk SP, Brown MA, **D'Amico AV**, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, McLeod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. *Urology* 60:1-6, 2002.
- **D'Amico AV**, Toupless G, Lopes L, Valentine K, Tempany C, Kumar S Marks P. Self Administration Of Untested Medical Therapies For The Treatment Of Prostate Cancer Can Lead To Clinically Significant Adverse Events, *Int J Radiat Oncol Biol Phys* 54:1311-1313; 2002..
- **D'Amico AV**, Cote K, Loffredo M, Renshaw AA, Chen MH. Pretreatment Predictors of Time to Cancer Specific Death after Prostate Specific Antigen Failure. *J Urol* 169:1320-1324, 2003.
- **D'Amico AV**, Moul J, Carroll P, Sun L, Lubeck D, Chen M. Cancer Specific Mortality Following Surgery or Radiation for Patients with Clinically Localized Prostate Cancer Managed During the PSA Era. *J Clin Oncol* 21:2163-72, 2003.
- **D'Amico AV**, Moul J, Carroll P, Sun L, Lubeck D, Chen M. Surrogate Marker For Prostate Cancer Specific Mortality Following Radical Prostatectomy Or Radiation Therapy. *J Natl Ca Inst* 95:1376-83, 2003.
- Punglia RS, **D'Amico AV**, Catalona WJ, Roehl KA, Kuntz KM. Effect of Verification Bias on Screening for Prostate Cancer with Prostate-Specific Antigen. *NEJM* 349:335-342, 2003.
- Talcott JA, Manola J, Clark JA, Kaplan I, Beard C, Mitchell SP, Chen R, O'Leary M., Kantoff PW, **D'Amico AV**. Time course and predictors of symptoms after primary prostate cancer therapy. *J Clin Oncol* 21:3979-3986, 2003.
- Lee AK, Doytchinova T, Chen MH, Renshaw AA, Weinstein M, Richie JP, **D'Amico AV**. Can the core length involved with prostate cancer identify clinically insignificant disease in low risk patients diagnosed on the basis of a single positive core? *Urologic Oncology* 21:123-128, 2003.
- Renshaw AA, Schultz D, Cote K, Loffredo M, Ziembra DE, **D'Amico AV**. Accurate Gleason grading of prostatic adenocarcinoma in prostate needle biopsies by general pathologists. *Arch Pathol Lab Med* 127:1007-1008, 2003.
- Beard CJ, Chen MH, Cote K, Loffredo M, Renshaw AA, Hurwitz M, **D'Amico AV**. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. *Int J Radiat Oncol Biol Phys* 58:19-24, 2004.
- Scher HI, Eisenberger M, **D'Amico AV**, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines

- for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. *J Clin Oncol.* 2004 22:537-56, 2004.
- Bloom K, Richie JP, Schultz D, Renshaw A, Saegaert T, **D'Amico AV**. Invasion of the Seminal Vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors. *Urology* 63:333-336, 2004.
  - **D'Amico AV**, Moul JW Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH. Intermediate End Point for Prostate Cancer-Specific Mortality Following Salvage Hormonal Therapy for Prostate-Specific Antigen Failure. *J Natl Ca Inst* 96:509-515, 2004.
  - Nguyen PL, Whittington R, Koo S, Schultz D, Cote KB, Loffredo M, Tempany CM, Titelbaum D,S, Schnall MD, Renshaw AA, Tomaszewski JE, **D'Amico AV**. Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys.* 59:400-5, 2004.
  - Jones GB, Xie L, El-Shafey A, Crasto CF, Bublely GJ, **D'Amico, AV**. Image contrast agents activated by prostate specific antigen (PSA). *Bioorg Med Chem Lett.* 14:3081-4, 2004.
  - **D'Amico AV**, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy. *N Engl J med* 2004;351:125-35.

**Anthony V. D'Amico, M.D., Ph.D. Disclosure**

The author stated no disclosures.